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Case report 
A 20-year-old female presented with classic symptoms of  
Cushing’s syndrome. The patient first noticed symptoms 
one year earlier. During that year, she complained of  a 60-
pound weight gain, amenorrhea, hirsutism, acne, bruising, 
and diffuse striae. Physical examination demonstrated 
moon facies, “buffalo hump,” and diffuse striae (abdomen, 
hip, buttock, breast, and lower extremity), as well as acne, 
bruising, and significant hirsutism (Figs. 1A-C).
Biochemical evaluation revealed elevation of  both corti-
sol (serum 26.0 µg/dL, normal range 5-23 µg/dL) and ad-
renocorticotropin hormone (ACTH) (32 pg/mL, normal 
range 5-27 pg/mL). Neither cortisol nor ACTH was sup-
pressed by a high- or low-dose dexamethasone suppression 
test. MRI of  the head with and without contrast (per-
formed to evaluate for a potential pituitary adenoma, given 
the elevated ACTH) revealed a possible microadenoma, 
although this was felt to be an unlikely source of  excess 
ACTH. Subsequently, a contrast-enhanced computed to-
mography (CT) scan of  the chest, abdomen, and pelvis was 
performed to search for an ectopic source of  ACTH pro-
duction. The CT revealed a 7x4cm, heterogeneous, lobu-
lated, left adrenal mass. Portions of  the mass showed poorly 
defined margins, raising suspicion for local invasion into 
the retroperitoneal fat (Figs. 2A-C). Contrast enhancement 
kinetics could not confirm an adrenal adenoma (relative 
percentage washout [RPW] of  24%), although this exami-
nation was not performed for dedicated adrenal mass 
evaluation (images were obtained at 75 seconds and 3 min-
utes per a standard abdominal CT protocol versus at 60 
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Figure 1. 20-year-old female with Cushing's syndrome. Photo-
graphs demonstrate the physical exam findings associated with 
Cushing’s Syndrome. A. Profile illustrates acne and hirsutism. B. 
Posterior-neck and upper-back view illustrates a typical “buffalo 
hump” and hirsutism. C. Lateral view of the abdomen illustrates 
abdominal striae.
seconds and 15 minutes per a dedicated adrenal mass pro-
tocol). Given the size of  the mass and clinical findings of  
hormonal hypersecretion, adrenal cortical carcinoma was 
the favored diagnosis. The right adrenal gland was normal, 
and there was no imaging evidence for distant metastasis 
within the chest, abdomen, or pelvis.
Given the presence of  an adrenal mass, additional bio-
chemical evaluation was ordered; it revealed elevation of  
dehydroepiandrosterone sulfate (DHEA-S) (697 ug/dL, 
normal range 145-395 ug/dL). Elevation of  multiple adre-
nal products, especially the sex hormone precursors 
DHEA-S and testosterone, also raised suspicion for carci-
noma. Metanephrines, prolactin, growth hormone, luteiniz-
ing hormone, and follicle-stimulating hormone were 
normal.
The patient underwent open surgery with en bloc resec-
tion of  the tumor. An elongated, lobulated, left adrenal 
mass weighing 136g was removed (Fig. 3). Afterward, the 
patient’s cortisol, DHEA, and ACTH levels returned to 
normal. Histopathological evaluation of  the specimen 
demonstrated an adrenal neoplasm with two large nodular 
foci of  extension into the surrounding fat. Grossly, the tu-
mor was friable, beige-tan, with areas of  pale yellow necro-
sis. On light microscopy, the vast majority of  the tumor 
showed a lobular-to-solid growth pattern with deeply eosi-
nophilic cytoplasm (Fig. 4a). A few vacuolated foci were 
present (Fig. 4b). The adrenocortical carcinoma (ACC) 
showed extensive infiltration into the adjacent fat (Fig. 4c). 
Marked cytologic atypia was noted, with nuclear enlarge-
ment and pleomorphism. Lipofuchsin pigment, typical for 
hormonally active tumors, was easily discernible. Pathol-
ogically, a tumor is defined as ACC when three of  the fol-
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Figure 3. 20-year-old female with Cushing's syndrome. Gross 
specimen.
Figure 4. 20-year-old 
female with Cushing's 
syndrome. On light mi-
croscopy, the vast major-
ity of the tumor showed a 
lobular-to-solid growth 
pattern with deeply eosi-
nophilic cytoplasm (A). A 
few vacuolated foci were 
present (B). The adreno-
cortical carcinoma (ACC) 
showed extensive infiltra-
tion into fat (C), and 
large nodular foci were 
present in separately 
submitted periadrenal 
soft tissue.
Figure 2. 20-year-old 
female with Cushing's 
syndrome. Abdominal 
CT images were ob-
tained in the axial (A), 
sagittal (B), and co-
ronal (C) planes, 75 
seconds after the 
administration of IV 
contrast. A heteroge-
neously enhancing 
mass measuring 
8x4.5x7cm arose from 
the left adrenal gland. 
Portions of the mass 
had ill-defined bor-
ders, and there was 
suggestion of invasion 
into the retroperito-
neal fat at the poste-
rior margin of the 
lesion (arrow). There 
was no evidence for 
invasion of the adja-
cent pancreas or 
kidney.
lowing histologic criteria are met: 1) high nuclear grade, 2) 
mitotic rate > 5 per 50 high-power fields, 3) atypical mito-
ses, 4) clear cells < 25%, 5) diffuse architectural pattern in 
more than one-third of  the tumor, 6) confluent necrosis, 7) 
venous invasion, 8) sinusoidal invasion, and 9) capsular in-
vasion (1). This tumor fulfilled five of  the criteria. Curi-
ously, despite the aggressive pattern of  invasion, mitotic 
figures were less than 5/50 hpf, and no atypical mitoses 
were noted. 
The invasion into surrounding tissue, in addition to the 
size of  the tumor, indicated a stage III ACC. After surgery, 
the patient underwent 45 days of  adjuvant external-beam 
radiation. The etiology of  the elevated ACTH levels in the 
setting of  ACC remains unclear. Furthermore, the tumor 
did not stain for ACTH (Fig. 5).
One year following surgery, the patient has returned to 
her baseline weight with near-complete resolution of  her 
Cushingoid habitus and hirsutism, and a return of  men-
struation. Followup abdominal and pelvic CT 11 months 
after surgery revealed no evidence of  local recurrence or 
distant metastasis.
Discussion
Patients with adrenocortical carcinoma (ACC) commonly 
present in one of  three clinical patterns. In approximately 
10% of  patients, an adrenal mass is discovered incidentally 
in an asymptomatic patient (adrenal incidentaloma). Ap-
proximately 30% of  patients present with symptoms of  a 
mass or mass effect but without clinical findings of  hyper-
secretion. The most common presentation, however, is one 
of  overt clinical symptoms suggesting hormone hypersecre-
tion of  the adrenal gland. This pattern accounts for 60% of 
cases and is more common in women under 40 years of  
age (2). Hypersecretion from an ACC accounts for 5-10% 
of  cases of  Cushing’s syndrome. The majority of  cases are 
corticotrophin-dependent, with the pituitary gland being 
the most common source of  ACTH hypersecretion (80%). 
10% of  cases occur as a result of  ectopic ACTH secretion 
(from a small-cell carcinoma, for instance), while the re-
maining 10% of  cases are corticotropin-independent (3). 
Adrenocortical tumors are the most common cause of  
corticotropin-independent Cushing’s syndrome (4, 5). 
A hormonal workup is essential before surgery is consid-
ered. At least 3 of  4 glucocorticoid tests should be per-
formed. Glucocorticoid tests include measurements of  
plasma ACTH, serum cortisol, 24-hour free urinary corti-
sol, and a dexamethasone suppression test (1mg, 2300 h) 
(6). Measuring serum levels of  sexual steroids and their 
precursors (DHEA-S, testosterone, androstendione) and/or 
mineralocorticoids may indicate an adrenal malignancy 
and determine the approach to treatment (6).
Imaging is essential in the diagnosis and pretreatment 
staging of  patients with suspected ACC. Magnetic reso-
nance imaging (MRI) and CT are the imaging modalities 
of  choice to localize a source of  hormonal hypersecretion 
as well as to assess for local invasion and distant metastasis 
(7). Imaging may also be useful in distinguishing an adrenal 
adenoma (benign lesion) from an ACC. The size of  an ad-
renal mass is one of  the best indicators of  malignancy. Ad-
renal adenomas are usually small (< 6 cm, typically be-
tween 2 and 3 cm). Masses measuring 6 cm or greater have 
a higher rate of  malignancy (~ 25%) and should be re-
sected (6). Adenomas are typically homogeneous; hetero-
geneity (often due to necrosis and/or hemorrhage) suggests 
malignancy. A subset of  adrenal adenomas have a high 
lipid content (lipid-rich adenomas) and can be reliably di-
agnosed on unenhanced CT (< 10 Hounsfield units) (8) 
and dual-phase gradient-echo MRI (signal loss on out-of-
phase gradient-echo images relative to in-phase gradien- 
echo images) (9, 10). Both adenomas and ACC enhance 
following administration of  intravenous contrast material. 
ACC typically enhances heterogeneously, while adenomas 
are typically more homogeneous. Moreover, although het-
erogeneity and large size are more reliable indicators of  
malignancy, assessment of  the temporal pattern of  contrast 
enhancement has also been described. Studies of  contrast 
kinetics have shown that adrenal adenomas demonstrate 
more rapid de-enhancement (or “washout” of  intravenous 
contrast material) relative to nonadenomatous adrenal le-
sions (such as ACC) (11, 12). Caoili et al (13) have de-
scribed a CT protocol consisting of  images obtained during 
three distinct phases: before administration of  contrast 
material (unenhanced), at a 50- to 80-sec delay following 
administration of  contrast material (enhanced), and at a 
15-min delay after administration of  contrast material (de-
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Figure 5. 20-year-old 
female with Cushing's 
syndrome. The tumor 
showed strong positivity 
for Melan A (A) and 
sparse positivity for syn-
aptophysin but was nega-
tive for chromogranin. 
Multiple blocks were 
stained for ACTH, all with 
negative findings (B). A 
Ki-67 showed 4.5 % posi-
tivity (C).
layed contrast-enhanced). Using this protocol, the degree of 
“washout” can be quantified as an absolute percentage 
washout (APW = [enhanced attenuation – delayed 
attenuation]/[enhanced attenuation – unenhanced attenua-
tion]) or, if  unenhanced images are not available, as a rela-
tive percentage washout (RPW = [enhanced attenuation – 
delayed attenuation]/enhanced attenuation) (8, 11). Ade-
nomas typically demonstrate rapid washout, which is de-
fined as an APW of  more than 60% and an RPW of  more 
than 40% on delayed images. Studies of  the contrast kinet-
ics of  ACC have shown that these lesions typically have a 
RPW of  <40% (11). Ill-defined margins and local invasion 
are additional imaging features suggestive of  malignancy. 
If  malignancy is suspected preoperatively, an open surgi-
cal approach is the standard of  care, given the aggressive 
nature and high local recurrence of  this disease. In the 
evaluation of  an adrenal mass, imaging findings are argua-
bly the most important factor used to dictate surgical ap-
proach (open, laparoscopic, versus retroperitoneoscopic). 
Considerations include size, aggressive appearance on im-
aging, and involvement of  the surrounding structures. 
Complete tumor resection with surrounding fatty/nodal 
tissue is indicated in all but stage IV disease (14-17). Exten-
sive surgery with resection of  invaded tissues may be re-
quired. It is crucial to avoid tumor spillage by maintenance 
of  the tumor capsule (2). 
In addition to surgery, Mitotane may be used to treat or 
control ACC. Mitotane is a cytotoxic drug that specifically 
targets adrenocortical cells. Hahner and Fassnacht found 
that treatment with Mitotane caused regression of  ACC 
tumors in 25% of  cases and was beneficial in controlling 
hormone levels in most patients (18). Radiation therapy is 
also performed palliatively for metastasis and locally ad-
vanced disease (19). Most recently, it has been found that 
the insulin-like growth factor (IGF) signaling pathway is 
thought to be important in the development and growth of  
ACC. The IGF pathway is activated by interactions be-
tween the circulating growth factors IGF-1 and IGF-2 and 
their membrane-bound receptor, IGF-1R. A number of  
agents are being developed that target this pathway by 
blocking the ability of  IGF-1 and IGF-2 to bind to and 
activate IGF-1R. One such agent is a monoclonal antibody 
called IMC-A12 (cixutumumab), with clinical trials spon-
sored by the NCI under way. Rosiglitazone is another im-
portant therapeutic drug targeting the IFG 2 receptor (20).
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